HDAC9 and synovial sarcoma: The combination of HDAC and proteasome inhibition synergizes to activate pro-apoptotic factors and bring about cell death and suppresses tumor growth in a murine model of synovial sarcoma, presenting a strong candidate strategy for clinical benefit in synovial sarcoma.